Novo Nordisk A/S’s shares fell by the most on record after patients using its experimental obesity shot CagriSema lost less ...

NVO is on track for its biggest daily and weekly percentage losses on record, as well as a fourth-straight loss. Shares now ...

Investors and analysts had eagerly awaited this data as a test of Novo’s case that it has a strong pipeline of drugs to ...

The long-standing edge that Novo Nordisk has held in the obesity drug market was thrown into question Friday when the company reported results of a closely watched candidate that fell short of ...

Novo Nordisk's stock suffered its biggest one-day slide on record after its latest obesity drug trial disappointed investors hoping for another blockbuster weight-loss drug. The Ozempic-maker's ...

(Bloomberg) -- Novo Nordisk A/S’s shares fell by the most on record after a failed attempt to leapfrog rival Eli Lilly & Co. in the red-hot market for obesity drugs. Novo’s experimental ...

Novo Nordisk’s shares fell by the most on record after patients using its experimental obesity shot CagriSema lost less weight than predicted in a study, throwing into question the drugmaker’s ...